SEC Form 4 · accession 0001209191-19-015559
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gabriel Leung
Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 4, 2019 · 4:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Mar 1, 2019 | M | 25,000 | $3.44 | A | 85,000 | D | |
| Ordinary SharesF2 | Mar 1, 2019 | S | 25,000 | $55.011 | D | 60,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF3 | $3.44 | Mar 1, 2019 | M | 25,000 | D | — | Sep 14, 2021 | Ordinary Shares | 25,000 | 74,743 | D |
Explanation of responses
- F1Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.
- F2On March 1, 2019, Mr. Leung sold 25,000 shares in multiple trades at prices ranging from $55.00 to $55.02. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3Fully vested as of the date hereof.